Literature DB >> 1360255

Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat.

E F Smith1, M J Slivjak, R Gagnon.   

Abstract

The purpose of this study was to evaluate the effects of carvedilol, a beta 1&2-adrenergic blocker and vasodilator, on cirazoline-mediated changes in arterial blood pressure and isoproterenol-mediated changes in heart rate after acute and chronic administration. Conscious, chronically instrumented male Sprague-Dawley rats were injected with carvedilol (1 mg/kg, IV), prazosin (0.3 mg/kg, IV), or propranolol (1 mg/kg, twice daily for 8 days. After administration of the first dose of carvedilol on day 1, the vasopressor response to cirazoline (60 +/- 3 mmHg predrug) and the isoproterenol-induced tachycardia (152 +/- 13 beats/min predrug) were blocked (e.g., 7 +/- 4 mmHg postdrug and 11 +/- 3 beats/min postdrug, respectively). After the administration of carvedilol on day 8, the cirazoline vasopressor response was 2 +/- 1 mmHg and the isoproterenol-induced tachycardia was 4 +/- 3 beats/min, indicating effective alpha 1- and beta-adrenergic blockade after chronic dosing with carvedilol. Prazosin blocked the cirazoline-induced vasopressor response on both days 1 and 8 but had no effect on the isoproterenol-induced tachycardia. Propranolol blocked the isoproterenol-induced tachycardia on both days 1 and 8 but had no effect on the cirazoline vasopressor response. These data indicate that only carvedilol effectively blocked both alpha- and beta-adrenergic hemodynamic responses and that the antagonism of these responses with carvedilol was not diminished after chronic dosing of twice-a-day treatment for 8 days.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360255     DOI: 10.1007/bf00055608

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  20 in total

1.  Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.

Authors:  E F Smith; M Jugus; L B Kinter
Journal:  Eicosanoids       Date:  1988

2.  In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol.

Authors:  A J Nichols; A C Sulpizio; D J Ashton; J P Hieble; R R Ruffolo
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

3.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

4.  Relationship between the antihypertensive effect and steady-state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.

Authors:  O Lederballe Pedersen; C K Christensen; E Mikkelsen; K D Rämsch
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

Review 5.  Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions.

Authors:  A J Man in't Veld; A H Van den Meiracker; M A Schalekamp
Journal:  Am J Hypertens       Date:  1988-01       Impact factor: 2.689

6.  Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.

Authors:  A J Nichols; M Gellai; R R Ruffolo
Journal:  Fundam Clin Pharmacol       Date:  1991       Impact factor: 2.748

7.  Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia.

Authors:  J C Kaski; L Rodriguez-Plaza; J Brown; A Maseri
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

8.  Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action.

Authors:  S M Jamal; S B Freedman; A Thomson; G Carter; P J Harris; D T Kelly
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

9.  Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol.

Authors:  L X Cubeddu; N Fuenmayor; F Varin; V G Villagra; R E Colindres; J R Powell
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

10.  The relationship between alterations in alpha 1-adrenoceptor reserve by phenoxybenzamine and benextramine and the sensitivity of cirazoline-induced pressor responses to inhibition by nifedipine.

Authors:  A J Nichols; R R Ruffolo
Journal:  Eur J Pharmacol       Date:  1986-07-31       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.